Lantheus Holdings, Inc
LNTH
$86.15
+0.38%
Lantheus Holdings, Inc. is a radiopharmaceutical-focused company that develops, manufactures, and commercializes diagnostic and therapeutic products to help clinicians find, fight, and follow diseases, primarily cancer. It operates as a key player in the specialized drug manufacturing industry, with a portfolio segmented into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships. The current investor narrative centers on the company's recovery and growth trajectory following a volatile period, driven by the commercial performance of its key oncology asset, PYLARIFY, and its strategic positioning within the expanding field of targeted radiopharmaceuticals, which is attracting significant attention as a transformative area in healthcare.…
LNTH
Lantheus Holdings, Inc
$86.15
LNTH 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Lantheus Holdings, Inc's 12-month outlook, with a consensus price target around $112.00 and implied upside of +30.0% versus the current price.
Average Target
$112.00
4 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
4
covering this stock
Price Range
$69 - $112
Analyst target range
Analyst coverage for LNTH appears limited, with only 4 analysts providing estimates for revenue and EPS, and no consensus price target or recommendation data provided in the dataset. The estimated EPS range for the forward period is wide, from $7.97 to $9.60, with an average of $8.44, while revenue estimates average $2.19 billion. The lack of a published consensus price target and the low analyst count typically indicate this is a mid-cap stock with limited institutional research coverage, which can lead to higher volatility and less efficient price discovery. Recent institutional rating actions show a mixed but generally stable sentiment, with firms like Mizuho and Citizens maintaining 'Outperform' ratings, and Truist upgrading from 'Hold' to 'Buy' in December 2025. However, Jones Trading downgraded from 'Buy' to 'Hold' in late February 2026, suggesting some divergence in views on near-term prospects. The wide EPS estimate range underscores the uncertainty and debate among the few covering analysts regarding the company's future earnings power.
Bulls vs Bears: LNTH Investment Factors
The evidence currently favors the bull case, driven by strong profitability, exceptional cash flow, a pristine balance sheet, and a powerful technical recovery that still has room to run. The forward P/E of 13.59x offers an attractive entry point for expected earnings growth. However, the bear case is anchored in modest revenue growth, margin compression, and the stock's history of severe volatility. The single most important tension in the investment debate is whether the company's earnings growth can accelerate sufficiently to justify and sustain the current recovery rally, or if margin pressures and volatile revenue will cause the stock to stall below its previous highs.
Bullish
- Strong Profitability & Cash Generation: Lantheus reported a robust net margin of 13.3% and operating margin of 18.97% in Q4 2025, with trailing twelve-month free cash flow of $348.64 million. This strong cash generation, coupled with a high return on equity of 21.43%, indicates the company can fund its growth internally without relying on debt.
- Powerful Technical Recovery Underway: The stock has gained 27.76% over the past three months and 48.21% over the past six months, significantly outperforming the SPY. Trading at $85.50, it remains 21.5% below its 52-week high of $108.91, suggesting room for further recovery, and a high short ratio of 5.85 could fuel additional upside through a short squeeze.
- Attractive Forward Valuation: The forward P/E ratio of 13.59x is significantly lower than the trailing P/E of 19.23x, indicating the market expects substantial earnings growth. This forward multiple is reasonable for a profitable healthcare company and sits below the stock's own historical peaks (e.g., 31.04x in Q3 2025), leaving room for multiple expansion.
- Rock-Solid Balance Sheet: The company has a virtually debt-free balance sheet with a debt-to-equity ratio of 0.0007 and a strong current ratio of 2.70. This minimal financial leverage significantly de-risks the investment and provides ample flexibility for strategic initiatives or weathering economic downturns.
Bearish
- Modest & Volatile Revenue Growth: Q4 2025 revenue grew only 4.01% year-over-year to $406.79 million, and the stock is still down 19.28% over the past year. Revenue has shown volatility quarter-to-quarter, and the company's recovery is heavily dependent on the performance of its key oncology asset, PYLARIFY.
- Gross Margin Compression: Gross margin compressed to 59.21% in Q4 2025 from 63.77% in Q2 2025. This 456 basis point decline could indicate product mix shifts, pricing pressures, or increased costs, posing a risk to the company's overall profitability if the trend continues.
- Limited Analyst Coverage & High Uncertainty: Only 4 analysts provide estimates, and there is no consensus price target, leading to less efficient price discovery and higher volatility. The wide range in forward EPS estimates ($7.97 to $9.60) underscores significant uncertainty about the company's future earnings power.
- Vulnerable to Full Recovery Failure: The stock remains 21.5% below its 52-week high. A failure to break through the key resistance at $108.91 could signal the recovery has stalled, potentially leading to a re-test of lower support levels. The stock's historical max drawdown of -53.92% highlights its potential for severe volatility.
LNTH Technical Analysis
The stock is in a strong recovery and uptrend phase, having gained 27.76% over the past three months and 48.21% over the past six months, significantly outperforming the broader market. Despite this recent strength, the stock remains down 19.28% over the past year, indicating it is recovering from a prior significant decline. Currently trading at $85.50, the price sits at approximately 78.5% of its 52-week range ($47.25 to $108.91), suggesting it has substantial momentum but is not yet at overextended highs, leaving room for further recovery toward previous peaks. Recent momentum is exceptionally strong, with the stock up 12.95% over the past month, far outpacing the SPY's 9.98% gain, indicating accelerating bullish sentiment. This short-term surge aligns with and reinforces the powerful 3-month uptrend, signaling a sustained recovery rather than a temporary bounce. The stock's beta of -0.125 is anomalous and suggests a historical low correlation to market moves, though recent relative strength figures (e.g., +23.62 vs. SPY over 3 months) show it is currently acting as a high-alpha play. Key technical levels are clearly defined, with major resistance at the 52-week high of $108.91 and support at the 52-week low of $47.25. A breakout above the $108.91 level would signal a full recovery of the prior downtrend and could open the path to new highs, while a breakdown below the recent consolidation area near $75 would threaten the recovery thesis. The stock's high short ratio of 5.85 indicates significant bearish positioning, which could fuel further upside on positive news or earnings through a short squeeze.
Beta
-0.08
-0.08x market volatility
Max Drawdown
-53.9%
Largest decline past year
52-Week Range
$47-$90
Price range past year
Annual Return
-17.8%
Cumulative gain past year
| Period | LNTH Return | S&P 500 |
|---|---|---|
| 1m | +13.5% | +11.4% |
| 3m | +32.8% | +8.3% |
| 6m | +68.7% | +9.4% |
| 1y | -17.8% | +31.3% |
| ytd | +28.1% | +7.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
LNTH Fundamental Analysis
Revenue growth has been modest but positive, with Q4 2025 revenue of $406.79 million representing a 4.01% year-over-year increase. Segment data reveals the Radiopharmaceutical Oncology line, driven by PYLARIFY ($240.2 million in the period), is the primary growth engine, while Precision Diagnostics contributed $143.25 million. The multi-quarter trend shows revenue has stabilized and begun growing sequentially from Q3's $384.01 million, suggesting the business is finding its footing after a period of volatility. The company is solidly profitable, reporting net income of $54.09 million in Q4 2025, translating to a net margin of 13.3%. Gross margin for the quarter was a healthy 59.21%, though it has compressed from the 63.77% seen in Q2 2025, potentially indicating product mix shifts or pricing pressures. Operating income of $77.18 million and an operating margin of 18.97% demonstrate the company's ability to convert revenue into earnings effectively. The balance sheet is exceptionally strong with minimal debt, evidenced by a debt-to-equity ratio of 0.0007, and robust liquidity with a current ratio of 2.70. The company generates substantial cash flow, with free cash flow over the trailing twelve months of $348.64 million and an operating cash flow of $90.18 million in the latest quarter. This strong cash generation, coupled with a high return on equity of 21.43%, indicates the company can fund its operations and growth internally without relying on external financing, significantly de-risking the investment.
Quarterly Revenue
$406786000.0B
2025-12
Revenue YoY Growth
+0.04%
YoY Comparison
Gross Margin
+0.59%
Latest Quarter
Free Cash Flow
$348639000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is LNTH Overvalued?
Given the company's positive net income, the primary valuation metric is the Price-to-Earnings (PE) ratio. The trailing PE ratio is 19.23x, while the forward PE is significantly lower at 13.59x, indicating the market expects substantial earnings growth in the coming year. The gap between trailing and forward multiples suggests analysts are forecasting a meaningful acceleration in profitability. Compared to sector averages, Lantheus's trailing PE of 19.23x appears reasonable for a profitable healthcare company with a growth profile, though a direct industry average PE is not provided in the data. Its Price-to-Sales ratio of 2.91x and EV/EBITDA of 10.24x offer additional context, suggesting the market is valuing the company on its earnings power rather than just sales. Historically, the stock's own PE ratio has been highly volatile, ranging from deeply negative figures during loss-making periods to over 30x during peak profitability quarters. The current trailing PE of 19.23x sits below the higher end of its historical range seen in 2024 (e.g., 31.04x in Q3 2025), suggesting the valuation is not stretched relative to its own history, especially considering the improved earnings stability. This positioning implies the market has not yet fully priced in a return to peak optimism, potentially leaving room for multiple expansion if growth continues.
PE
19.2x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -498x~40x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
10.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: The primary financial risk is not leverage but earnings volatility and margin pressure. Revenue growth is modest at 4.01% YoY, and gross margin has compressed by 456 basis points over two quarters, from 63.77% to 59.21%. This indicates potential pricing or mix challenges in the core Radiopharmaceutical Oncology segment, which contributed $240.2M in Q4. Furthermore, the company's recent profitability follows a period of losses (Q4 2024 net income was -$11.79M), demonstrating earnings instability that could resurface if growth stalls.
Market & Competitive Risks: The stock trades at a forward P/E of 13.59x, which is reasonable but not deeply discounted, leaving it vulnerable to multiple compression if growth expectations are not met. Operating in the competitive and regulation-heavy radiopharmaceutical space, Lantheus faces constant innovation risk from larger peers. The stock's anomalous beta of -0.125 suggests a historical lack of correlation to the market, but its recent high-alpha performance makes it susceptible to sector rotation out of healthcare or growth stocks. The limited analyst coverage (4 analysts) exacerbates these risks by contributing to potential mispricing and sharp reactions to news.
Worst-Case Scenario: The worst-case scenario involves a combination of accelerated gross margin erosion, a significant slowdown in PYLARIFY adoption, and a broader market downturn that hits recovery stocks hardest. This could trigger analyst downgrades, a short-covering rally reversal, and a loss of technical momentum. In this adverse scenario, the stock could realistically retreat to re-test its 52-week low of $47.25, representing a potential loss of approximately -45% from the current price of $85.50. The historical max drawdown of -53.92% provides a precedent for such severe downside volatility.